The mixed earnings report may initially concern investors, but the revenue growth from gene therapy sales and the strategic deal with Arrowhead are positive indicators for future growth. The addition of new clinical programs further strengthens Sarepta's pipeline, likely leading to a positive short-term impact on the stock.